Physician profile
Samuel H Markind
NPI 1427053404
$2,209.72
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $30.82 · 2021: $1,750 · 2022: $88.67.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $1,750.00 | 2021-2022 | |
| Lilly USA, LLC | $88.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.57 | 2019 | |
| Biogen, INC. | $51.56 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.99 | 2019 | |
| Csl Behring | $29.14 | 2019 | |
| Livanova USA, INC. | $24.68 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.18 | 2019 | |
| Bausch Health US, LLC | $20.19 | 2019 | |
| Portola Pharmaceuticals, LLC | $18.06 | 2019 | |
| Acadia Pharmaceuticals INC | $18.02 | 2019 | |
| Allergan, INC. | $16.84 | 2019 | |
| Lundbeck LLC | $16.79 | 2020 | |
| Ge Healthcare | $14.03 | 2020 | |
| Abbvie INC. | $12.08 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.71 | 2019 | |
| Strongbridge US INC. | $11.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$14,377.69 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Markind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.